Diagnostic Accuracy of Glycated Haemoglobin and Average Glucose Values in Type 2 Diabetes Mellitus Treated with Premixed Insulin.

Average blood glucose Glycated haemoglobin HbA1c Premixed insulin Type 2 diabetes

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 23 10 2018
pubmed: 9 2 2019
medline: 9 2 2019
entrez: 9 2 2019
Statut: ppublish

Résumé

Studies assessing the relationship between glycated haemoglobin (HbA1c) and average blood glucose (ABG) were conducted in small groups of patients on different treatments and may be biased for these reasons. The aim of the study was to assess the relationship between HbA1c and ABG in a large group of type 2 diabetes patients treated with premix insulin. In 4257 patients treated with premixed insulin, the parallel point-of-care assessment of HbA1c and ABG from the preceding 90 days (ABG90), calculated automatically from all values measured by the glucometer, was performed twice. The regression formulas and respective values of HbA1c and ABG90 were calculated. The mean number of recorded glucose values/patient was 2.37 estimations per day. The regression formula calculated using data from the first assessment was HbA1c = 5.28 + 0.01487 × ABG90 and that using data from the second one was HbA1c = 4.78 + 0.01683 × ABG90. The slopes of the regression lines are lower than that in a similar analysis from the A1c-Derived Average Glucose (ADAG) study. The comparison of ADAG formula and the formula derived from the present study shows that both formulas give similar results at low HbA1c values, but differ at higher HbA1c values. Additionally, the 95% confidence interval is broader in the PROGENS study e.g. a 95% probability of certainty that the actual HbA1c value was greater than 7.0% (53 mmol/mol) was achieved only at an ABG90 value of 220 mg/dL. The relationship between HbA1c and ABG estimations may be different in various patients; therefore, it seems that the use of one equation in all populations may not be reliable. Broad assessment of ABG as a tool that may replace HbA1c measurements should be recommended only with caution, providing the possible limitations and confidence intervals. Bioton S.A.

Identifiants

pubmed: 30734901
doi: 10.1007/s13300-019-0570-1
pii: 10.1007/s13300-019-0570-1
pmc: PMC6437248
doi:

Types de publication

Journal Article

Langues

eng

Pagination

587-596

Références

Diabetes Care. 2008 Aug;31(8):1473-8
pubmed: 18540046
Fam Pract. 2010 Feb;27(1):17-24
pubmed: 19969524
Diabetes Care. 2009 Jan;32 Suppl 1:S13-61
pubmed: 19118286
MMWR Surveill Summ. 2011 May 20;60(6):1-44
pubmed: 21597458
Clin Chem Lab Med. 2010 May;48(5):609-14
pubmed: 20464776
Diabetes Care. 2002 Feb;25(2):275-8
pubmed: 11815495
J Intern Med. 2013 Mar;273(3):283-93
pubmed: 23121487
Arch Med Sci. 2016 Oct 1;12(5):985-991
pubmed: 27695488
J Clin Endocrinol Metab. 2012 Apr;97(4):1067-72
pubmed: 22238408
Diabetes Care. 2011 Jun;34(6):1419-23
pubmed: 21617111
Diabetes Care. 2010 Jan;33(1):61-6
pubmed: 19808928
Diabetes. 2001 Dec;50(12):2858-63
pubmed: 11723071
Diabetes Care. 2012 Dec;35(12):2674-80
pubmed: 23173136
Diabetes Care. 2017 Jan;40(Suppl 1):S48-S56
pubmed: 27979893
South Med J. 2015 Dec;108(12):724-9
pubmed: 26630892
Diabetes Care. 2017 Jan;40(Suppl 1):S11-S24
pubmed: 27979889
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Clin Chem. 2011 Apr;57(4):568-76
pubmed: 21368238
Ir J Med Sci. 1994 May;163(5):233-5
pubmed: 8045728
J Diabetes Sci Technol. 2009 May 01;3(3):429-38
pubmed: 20144279
Clin Chem. 2014 Aug;60(8):1062-72
pubmed: 24865164
Curr Diab Rep. 2011 Dec;11(6):562-9
pubmed: 21975967
BMJ Open. 2015 Mar 12;5(3):e006277
pubmed: 25765020
Diabetes Res Clin Pract. 2011 Sep;93(3):312-3
pubmed: 21820751
Diabetes Care. 2003 Mar;26(3):881-5
pubmed: 12610053
Diabetes Care. 2014 Apr;37(4):1048-51
pubmed: 24513588
Arch Public Health. 2015 Sep 25;73:43
pubmed: 26413295

Auteurs

Magdalena Walicka (M)

Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the Ministry of the Inferior and Administration, Warsaw, Poland.

Jacek Jozwiak (J)

Department of Public Health, Czestochowa University of Technology, Czestochowa, Poland.
Silesian Analytical Laboratories, Katowice, Poland.

Jacek Rzeszotarski (J)

Clinical Department of Internal Diseases and Diabetology, 10th Military Hospital, Bydgoszcz, Poland.

Anna Zonenberg (A)

Medical Institute, Higher School of Computer Science and Business Administration, Lomza, Poland.

Malgorzata Masierek (M)

Bioton SA, Warsaw, Poland.

Pawel Bijos (P)

Private Practice, Warsaw, Poland.

Edward Franek (E)

Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital of the Ministry of the Inferior and Administration, Warsaw, Poland. edward.franek@cskmswia.pl.
Department of Human Epigenetics, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. edward.franek@cskmswia.pl.

Classifications MeSH